Onco-Innovations Partners with Redwood AI for PNKP Inhibitor Development

Onco-Innovations Limited has entered into a strategic agreement with Redwood AI Inc. to advance its PNKP inhibitor technology for cancer treatment. This collaboration aims to enhance the development of Onco's Polynucleotide Kinase Phosphatase compound, designed to increase sensitivity to radiation and DNA-damaging therapies in solid tumors. Redwood AI's advanced chemistry tools are expected to streamline drug development by reducing synthesis complexity and refining compound design.

Under the agreement, Redwood AI will offer support in synthesis evaluation, cheminformatics, and organ-specific toxicity prediction. These efforts will bolster Onco's technical capabilities at a crucial preclinical phase, with the intent to improve safety and discovery precision as the company progresses towards First-in-Human studies.

Thomas O'Shaughnessy, CEO of Onco-Innovations, highlighted the potential of Redwood AI's platform to optimize compound design and accelerate the company's timeline towards clinical trials.